Startups
Apertura is a biotechnology company opening opportunities in gene therapy for treating debilitating diseases with limited options. We are pioneering next-generation AAV gene therapies by simultaneously engineering capsids, regulatory elements, and payloads to overcome current limitations in genetic medicine. Founded on technologies from the Broad Institute and Harvard University, and with support from Deerfield Management Company, we are located at the Cure in New York City.
Overview
Location
United States, New York
Employees
11-50
Total raised
$67M
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 3
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| May 16, 2024 | New gene delivery vehicle shows promise for human brain gene therapy | In an important step toward more effective gene therapies for brain diseases, researchers from the Broad Institute of MIT and Harvard have engineered a gene-delivery vehicle that uses a human protein to efficiently cross the blood-brain bar... |
| Apr 28, 2022 | Has Elon Musk already broken his merger agreement with Twitter? | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Elon Musk has been tweeting this week in reference to the Twitter deal—which is, in fact, allowed... |
Reviews 0
FAQ about Apertura Gene Therapy
How much funding has Apertura Gene Therapy raised?
Apertura Gene Therapy has raised $67M in total across 1 funding round.
What has the press written about Apertura Gene Therapy?
Parsers VC has collected 3 articles mentioning Apertura Gene Therapy, among them “New gene delivery vehicle shows promise for human brain gene therapy” (May 16, 2024) and “Has Elon Musk already broken his merger agreement with Twitter?” (Apr 28, 2022).
Is Apertura Gene Therapy still active?
Apertura Gene Therapy is probably closed: its latest activity on Parsers VC dates from Apr 27, 2026.